Advertisement
Feature Article

Eliminating hepatitis C: Part 3. Curing hepatitis C in general practice

TARA PURCELL, AMANDA WADE, LISA ACCADIA, Simone Strasser, Phillip Read, NICOLE ALLARD, David Baker, ALISA PEDRANA, JOSEPH DOYLE

Figures

© KATERYNA_KON/STOCK.ADOBE.COM
© KATERYNA_KON/STOCK.ADOBE.COM

Abstract

Most patients with hepatitis C are treated with pangenotypic direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir. GPs experienced in the management of hepatitis C can prescribe DAAs independently. Others must consult with a specialist before prescribing; online resources can streamline this process. Important considerations before prescribing include barriers to adherence and drug interactions.

Key Points

  • Most people with hepatitis C can be treated with direct-acting antiviral (DAA) therapy in primary care.
  • Pangenotypic DAA regimens that are well tolerated and effective against all hepatitis C genotypes include sofosbuvir/velpatasvir and glecaprevir/pibrentasvir.
  • GPs who are experienced in the management of hepatitis C can prescribe DAAs independently, whereas others must consult with a specialist by phone, fax or email before DAA prescribing; online resources are available to facilitate this process.
  • Considerations before prescribing DAAs include barriers to adherence and interactions between DAAs and prescribed medications and other drugs the patient takes.
  • Clinical support, tools and resources to help GPs treat hepatitis C are available online.

Figures

© KATERYNA_KON/STOCK.ADOBE.COM
© KATERYNA_KON/STOCK.ADOBE.COM